Tyra Biosciences (Tyra Biosciences) Cash-to-Debt : 58.96 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tyra Biosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 58.96.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tyra Biosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Tyra Biosciences's Cash-to-Debt or its related term are showing as below:

TYRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 97.74 Max: 266.91
Current: 58.96

During the past 5 years, Tyra Biosciences's highest Cash to Debt Ratio was 266.91. The lowest was 0.43. And the median was 97.74.

TYRA's Cash-to-Debt is ranked better than
73.93% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs TYRA: 58.96

Tyra Biosciences Cash-to-Debt Historical Data

The historical data trend for Tyra Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tyra Biosciences Cash-to-Debt Chart

Tyra Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.43

107.21

255.44

95.81

31.32

Tyra Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												93.39	38.28	35.28	31.32	58.96

Competitive Comparison of Tyra Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Tyra Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Cash-to-Debt falls into.

Tyra Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tyra Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	203.469	/	(0.28	+	6.216)
	=	31.32

Tyra Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	382.462	/	(0.37	+	6.117)
	=	58.96

Tyra Biosciences (NAS:TYRA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tyra Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyra Biosciences (Tyra Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2656 State Street, Carlsbad, CA, USA, 92008

Website

https://www.tyra.bio

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its lead product candidate is TYRA-300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Executives

Daniel Bensen	officer: Chief Operating Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Todd Harris	director, officer: Chief Executive Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alan Fuhrman	officer: Chief Financial Officer	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Ali D. Fawaz	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J More	director, 10 percent owner	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Alta Partners Nextgen Fund Ii, L.p.	10 percent owner	4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert L. Hudkins	officer: Chief Technology Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Melissa Mccracken	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008